Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

Completed · Not applicable

Conditions studied: Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome

In brief

OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II. Determine the toxicity of this drug in these patients.

Key facts

Study ID

NCT00010400

Run by

Johns Hopkins University

People needed

35

Starts

1997-04-01

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
• Johns Hopkins Oncology Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.